Chemical formula: C₂₅H₃₆N₃O₉PS Molecular mass: 585.607 g/mol PubChem compound: 131536
Fosamprenavir after oral administration, is rapidly and almost completely hydrolysed to amprenavir and inorganic phosphate prior to reaching the systemic circulation. Amprenavir binds to the active site of HIV-1 protease and thereby prevents the processing of viral gag and gag-pol polyprotein precursors, resulting in the formation of immature noninfectious viral particles.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J05AE07 | Fosamprenavir | J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AE Protease inhibitors |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| TELZIR Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Fosamprenavir is an active ingredient of these brands:
United States (US)
Australia (AU)
Austria (AT)
Brazil (BR)
Canada (CA)
Croatia (HR)
Cyprus (CY)
Estonia (EE)
Finland (FI)
France (FR)
Ireland (IE)
Italy (IT)
Japan (JP)
Lithuania (LT)
Mexico (MX)
Netherlands (NL)
Poland (PL)
Romania (RO)
South Africa (ZA)
Spain (ES)
Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
